Prima BioMed (IMMP)
(Delayed Data from NSDQ)
$2.01 USD
+0.01 (0.50%)
Updated Jul 11, 2024 04:00 PM ET
After-Market: $2.75 +0.74 (36.82%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
IMMP 2.01 +0.01(0.50%)
Will IMMP be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for IMMP based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IMMP
Prima BioMed (IMMP) Loses -34.84% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Immutep (IMMP) Up on Initial Data From Lung Cancer Study
IMMP: What are Zacks experts saying now?
Zacks Private Portfolio Services
Immutep (IMMP) Surges 65% on Upbeat Lung Cancer Study Data
Other News for IMMP
Immutep Reports Positive Results in First Line Head and Neck Squamous Cell Carcinoma Patients with Negative PD-L1 Expression
Immutep Announces Details for Oral Presentation at ESMO Virtual Plenary Session and Webcast to Discuss Clinical Results
Immutep’s Promising Cancer Treatment Trial Results
Levi Strauss Posts Mixed Results, Joins Walgreens, AeroVironment And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Wall Street Analysts Are Bullish on Top Healthcare Picks